scholarly journals Innovative oral sucrosomial ferric pyrophosphate-based supplementation rescues suckling piglets from iron deficiency anemia similarly to commonly used parenteral therapy with iron dextran

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Mateusz Szudzik ◽  
Rafał Mazgaj ◽  
Paweł Lipiński ◽  
Robert Staroń ◽  
Aneta Jończy ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Mammalian Species ◽  
Preventive Therapy ◽  
Postnatal Period ◽  
Deficiency Anemia ◽  
Iron Dextran ◽  
Iron Supplement ◽  
Ferric Pyrophosphate ◽  
Physiological Values

AbstractIron deficiency is the most common mammalian nutritional deficiency during the neonatal period. However, among mammalian species neonatal iron deficiency anemia (IDA), the most severe consequence of iron scarcity, occurs regularly in pigs. Although intramuscular supplementation of piglets with high amounts of iron dextran (FeDex) is largely considered an appropriate preventive therapy for IDA prophylaxis, an increasing evidence shows that it negatively affects pig physiology. The aim of our study was to evaluate the efficacy of non-invasive supplementation of piglets with sucrosomial ferric pyrophosphate (SFP), a highly bioavailable dietary iron supplement in preventing IDA, in humans and mice. Results of our study show that SFP given to piglets per os in the amount of 6 mg Fe daily efficiently counteracts IDA at a rate comparable with the traditional FeDex-based supplementation (100 mgFe/kG b.w.; i.m. injection). This was indicated by physiological values of red blood cell indices and plasma iron parameters measured in 28-day old piglets. Moreover, SFP-supplemented piglets showed significantly lower (P ≤0.05) plasma level of 8-isoprostane, a biomarker for oxidative stress compared to FeDex-treated animals, implying lesser toxicity of this order of iron replenishment. Finally, supplementation with SFP does not increase considerably the blood plasma hepcidin, a peptide that acts to inhibit iron absorption from the diet. SFP emerges as a promising nutritional iron supplement, with a high potential to be adopted in the postnatal period.

scholarly journals Comparative Evaluation of Sucrosomial Iron and Iron Oxide Nanoparticles as Oral Supplements in Iron Deficiency Anemia in Piglets

2021 ◽  
Vol 22 (18) ◽  
pp. 9930
Author(s):  
Rafał Mazgaj ◽  
Paweł Lipiński ◽  
Mateusz Szudzik ◽  
Aneta Jończy ◽  
Zuzanna Kopeć ◽  
...  
Keyword(s):  
Iron Oxide ◽  
Iron Deficiency ◽  
Iron Oxide Nanoparticles ◽  
Iron Deficiency Anemia ◽  
Iron Homeostasis ◽  
Mammalian Species ◽  
Deficiency Anemia ◽  
Oxide Nanoparticles ◽  
Iron Supplement ◽  
Nutritional Disorder

Iron deficiency is the most common mammalian nutritional disorder. However, among mammalian species iron deficiency anemia (IDA), occurs regularly only in pigs. To cure IDA, piglets are routinely injected with high amounts of iron dextran (FeDex), which can lead to perturbations in iron homeostasis. Here, we evaluate the therapeutic efficacy of non-invasive supplementation with Sucrosomial iron (SI), a highly bioavailable iron supplement preventing IDA in humans and mice and various iron oxide nanoparticles (IONPs). Analysis of red blood cell indices and plasma iron parameters shows that not all iron preparations used in the study efficiently counteracted IDA comparable to FeDex-based supplementation. We found no signs of iron toxicity of any tested iron compounds, as evaluated based on the measurement of several toxicological markers that could indicate the occurrence of oxidative stress or inflammation. Neither SI nor IONPs increased hepcidin expression with alterations in ferroportin (FPN) protein level. Finally, the analysis of the piglet gut microbiota indicates the individual pattern of bacterial diversity across taxonomic levels, independent of the type of supplementation. In light of our results, SI but not IONPs used in the experiment emerges as a promising nutritional iron supplement, with a high potential to correct IDA in piglets.

scholarly journals Management of postpartum iron deficiency anemia: review of literature

2018 ◽  
Vol 8 (1) ◽  
pp. 338
Author(s):  
Mohamed Saber ◽  
Mohamed Khalaf ◽  
Ahmed M. Abbas ◽  
Sayed A. Abdullah
Keyword(s):  
Iron Deficiency ◽  
Blood Transfusion ◽  
Iron Deficiency Anemia ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Ferric Carboxymaltose ◽  
Allogenic Blood Transfusion ◽  
Iron Dextran ◽  
Peripheral Tissues ◽  
Iv Iron

Anemia is a condition in which either the number of circulating red blood cells or their hemoglobin concentration is decreased. As a result, there is decreased transport of oxygen from the lungs to peripheral tissues. The standard approach to treatment of postpartum iron deficiency anemia is oral iron supplementation, with blood transfusion reserved for more server or symptomatic cases. There are a number of hazards of allogenic blood transfusion including transfusion of the wrong blood, infection, anaphylaxis and lung injury, any of which will be devastating for a young mother. These hazards, together with the national shortage of blood products, mean that transfusion should be viewed as a last resort in otherwise young and healthy women. Currently, there are many iron preparations available containing different types of iron salts, including ferrous sulfate, ferrous fumarate, ferrous ascorbate but common adverse drug reactions found with these preparations are mainly gastrointestinal intolerance like nausea, vomiting, constipation, diarrhoea, abdominal pain, while ferrous bis-glycinate (fully reacted chelated amino acid form of iron) rarely make complication. Two types of intravenous (IV) preparations available are IV iron sucrose and IV ferric carboxymaltose. IV iron sucrose is safe, effective and economical. Reported incidence of adverse reactions with IV iron sucrose is less as compared to older iron preparations (Iron dextran, iron sorbitol), but it requires multiple doses and prolonged infusion time. Intramuscular iron sucrose complex is particularly contraindicated because of poor absorption. It was also stated that when iron dextran is given intravenously up to 30% of patients suffer from adverse effects which include arthritis, fever, urticaria and anaphylaxis.

Concomitant Administration of Oral Iron Supplement with Antisecretory Agents among Hospitalized Adults with Iron Deficiency Anemia

2019 ◽  
Vol 119 (9) ◽  
pp. A22
Author(s):  
C. Sanchez ◽  
V. Rodriguez Aponte ◽  
A. Cintron Rosado ◽  
J. Molina Cruz ◽  
J. Morales Irizarry ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Concomitant Administration ◽  
Oral Iron ◽  
Deficiency Anemia ◽  
Iron Supplement

scholarly journals Effects of Iron Deficiency Anemia and Its Rapid Correction on the Serum Metabolomic Profile of Rhesus Infants

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 1070-1070
Author(s):  
Brian Sandri ◽  
Gabriele Lubach ◽  
Eric Lock ◽  
Michael Georgieff ◽  
Pamela Kling ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Acid Production ◽  
Iron Status ◽  
Deficiency Anemia ◽  
Iron Dextran ◽  
Metabolomic Profile ◽  
Intramuscular Injections ◽  
Iron Deficient ◽  
Rapid Correction

Abstract Objectives To determine whether rapid correction of iron deficiency using intramuscular iron dextran normalizes serum metabolomic changes in a nonhuman primate model of iron deficiency anemia (IDA). Methods Blood was collected from naturally iron-sufficient (IS; n = 10) and IDA (n = 12) male and female infant rhesus monkeys (Macaca mulatta) at 6 months of age. IDA infants were treated with intramuscular injections of iron dextran, 10 mg/weekly for 4–8 weeks. Iron status was reevaluated following treatment using hematological measurements and sera were metabolically profiled using HPLC/MS with isobaric standards for identification and quantification. Results Early-life iron deficiency anemia negatively affects many cellular metabolic processes, including energy production, electron transport, and oxidative degradation of toxins. Slow iron repletion with dietary supplementation restores iron deficient monkeys from a hematological perspective, but the serum metabolomic profile remains differed from monkeys that had been iron sufficient their entire life. Whether rapid iron restoration through intramuscular injections of iron dextran normalizes serum metabolomic profile is not known. A total of 654 metabolites were measured with differences in 53 metabolites identified between IS and IDA monkeys at 6 months (P 0.05). Pathway analyses provided evidence of altered liver function, hypometabolic state, differential essential fatty acid production, irregular inosine and guanosine metabolism, and atypical bile acid production in IDA infants. After treatment, iron-related hematological parameters had recovered, but the formerly IDA infants remained metabolically distinct from the IS infants, with 225 metabolites differentially expressed between the groups. Conclusions As with slow iron repletion, rapid iron repletion does not normalize the altered serum metabolomic profile in rhesus infants with IDA, suggesting the need for iron supplementation in the pre-anemic stage. Funding Sources National Institutes of Health.

Optimizing Clinical Status and Quality of Life With Iron Dextran in Gynecologic Patients With Iron Deficiency Anemia [8L]

2019 ◽  
Vol 133 (1) ◽  
pp. 130S-131S
Author(s):  
Ghadear Shukr ◽  
Haleema Saeed ◽  
Marian Girgis ◽  
Aparna Basu ◽  
Phillip Kuriakose ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Clinical Status ◽  
Deficiency Anemia ◽  
Iron Dextran ◽  
Gynecologic Patients

What Is the Best Test for Iron Deficiency?

PEDIATRICS ◽  
1983 ◽  
Vol 72 (6) ◽  
pp. 909-910
Author(s):  
MARK S. DINE
Keyword(s):  
At Risk ◽  
Iron Deficiency ◽  
Physical Examination ◽  
Iron Deficiency Anemia ◽  
Screening Test ◽  
Deficiency Anemia ◽  
Iron Dextran ◽  
Children At Risk ◽  
Primary Physician

To the Editor.— We are indebted to Oski et al1 and to the 38 children who received injections of iron dextran for demonstrating the importance of determining not only which children had iron deficiency anemia but also those with iron deficiency without anemia. However, the primary physician needs a screening test that is efficient and not costly. Unfortunately, the history and physical examination are not effective screens for the identification of children at risk—with the exception of those children drinking in excess of one quart of milk a day.2

Sign in / Sign up

Export Citation Format

Share Document